|As at: 21 April 2008
|Scoping a possible audit
|Tendering in progress
|In development or piloting
ACP Association of Coloproctologists of Great Britain and Ireland, ASA Ambulance Services Association, AUGIS Association of Upper GI Surgeons, BAHNO British Association of Head and Neck Oncologists, BCIS British Cardiac Intervention Society, BOA British Orthopaedic Association, BSH British Society for Heart Failure, HRUK Heart Rhythm UK, NCD National Clinical Director, NCASP National Clinical Audit Support Programme (part of Health and Social Care Information Centre, HSCIC), RA Renal Association, RCNI Royal College of Nursing Institute, RCP Royal College of Psychiatrists, RCPCH Royal College of Paediatrics and Child Health, RCPsychiat Royal College of Psychiatrists, SCTS Society for Cardiothoracic Surgery, UCLH University College Hospital London, Univ. Birm. University of Birmingham Department of Primary Care and General Practice, VSGBI Vascular Society of Great Britain and Ireland.
Mr. Lansley: To ask the Secretary of State for Health what the evidential basis is for the statement in the impact assessment on the statutory scheme to control prices of branded NHS medicines that any change in UK pricing will have a negligible effect on the viability of these global businesses. 
Dawn Primarolo: The Department's Consultation on a Statutory Scheme to Control the Price of Branded NHS Medicines and the accompanying impact assessment, issued on 18 June 2008, set out how the proposed measures that are subject to consultation are estimated to result in a lost profits to the pharmaceutical industry of £280 million a year. The United Kingdom comprises only 3.5 per cent. of the global market and in patent medicine prices will continue to be significantly greater than manufacturing and distribution costs. Therefore the Department has concluded that, although there will be an impact on profits for the global pharmaceutical industry as a result of the proposed measures, these will not be significant enough to affect the viability of global pharmaceutical companies.
The part of the consultation dealing with the price cut and measures to limit the price of out of patent brands ends on 25 September 2008. The consultation document invites comments on the impact assessment, in particular the analysis of costs and benefits. Copies of Consultation on a Statutory Scheme to Control the Price of Branded NHS Medicines have been placed in the Library and are also available on the Department's website at:
Mr. Bradshaw: A specified date has yet to be confirmed for revenue allocations to primary care trusts for 2009-10 and 2010-11 but the intention is that this will be announced before the summer recess.
Ann Keen: This information is not collected centrally. The non-medical census which collects data on numbers includes directors within the 'senior managers' category but this is not sub-divided in more detail.
Ann Keen: The healthy workplaces handbook is produced by NHS Employers, who represent trusts in England on workforce issues. The handbook includes a section on mental health and employment, which provides national health service managers and occupational health professionals with the tools they need to assess the suitability of persons having mental health problems who wish to work or train, or who are already working in the service.
Mr. Stephen O'Brien:
To ask the Secretary of State for Health pursuant to the Answer of 3 June 2008,
Official Report, columns 910-11W, on the NHS: personal records, if he will break down the number of nutrition-related adverse incidents reported to the National Reporting and Learning System by area of incident.